I checked with Google Gemini Flash:
Is there scientific and clinical evidence that glycine, when dosed at 3 to 5 grams, will raise or lower blood glucose levels by itself?
Gemini Response:
When administered alone in a fasting state, a single oral dose of 3 to 5 grams of glycine does not significantly raise or lower systemic blood glucose levels. Clinical evidence indicates that isolated glycine induces glycemic neutrality due to simultaneous, counterbalancing endocrine responses.
Clinical Evidence: Standalone Administration
-
Glycemic Stability: In a clinical study by Gannon et al. (2002), healthy subjects received an oral dose of glycine adjusted to lean body mass (~3.6 to 5.0 g) either alone with water or alongside oral glucose. When ingested alone,plasma glucose concentrations remained flat and did not significantly differ from baseline or from a plain water control over a two-hour sampling window.
-
Insulin Stimulation: A clinical trial by GonzĂĄlez-Ortiz et al. (2001) evaluated an oral bolus of 5 g of glycine in healthy first-degree relatives of type 2 diabetics. Glycine elicited a statistically significant increase in early, late, and total insulin secretion without inducing clinical hypoglycemia or altering baseline insulin sensitivity.
-
Longer-Term Fasting Parameters: In a 2025 trial published by Tan et al. (2025), two weeks of daily glycine supplementation (~0.1 g/kg/day, roughly 8â10 g/day in obese adults) resulted in no significant change in fasting plasma glucose, fasting insulin, or mixed-meal tolerance test (MMTT) glucose area under the curve (AUC).
Standalone vs. Postprandial Context
The metabolic behavior of glycine changes entirely when carbohydrates are present. In the Gannon et al. trial, co-ingesting glycine with 25 g of glucose cut the postprandial glucose AUC by over 50% relative to glucose alone. This blunting effect occurs without an increase in total insulin AUC, pointing toward accelerated glucose disposal mediated by enteroendocrine signaling (such as glucagon-like peptide-1, or GLP-1). When taken by itself , however, this postprandial clearing mechanism remains inactive because no exogenous glucose load is present to clear.
National Institutes of Health (NIH) | (.gov)
Scholarly Debates and Knowledge Gaps
- Continuous Glucose Monitoring (CGM) Granularity: Most clinical trials examining standalone glycine relied on intermittent venous sampling over 120 to 180 minutes. Granular interstitial data capturing transient micro-fluctuations (e.g., during nocturnal dosing for sleep architecture) in normoglycemic and prediabetic cohorts remain sparse.
- Metabolic Phenotypes: Most acute dosing trials involve young, metabolically healthy cohorts. In individuals with severe hepatic insulin resistance, non-alcoholic fatty liver disease (NAFLD/MASLD), or hyperglucagonemia, a 5 g glycine challenge might theoretically skew hepatic glucose output differently if αα-cell suppression is impaired,though clinical verification of this specific scenario is lacking.
- Chronic Glycemic Markers (HbA1c): While an acute bolus does not lower blood glucose, chronic daily intake (3 to 15 g/day) in diabetic cohorts has shown small reductions in HbA1c in preliminary trials (e.g., Cruz et al., 2008).This is generally attributed to decreased systemic inflammation, advanced glycation end-product (AGE) inhibition,and enhanced glutathione synthesis rather than direct hypoglycemic action.
If the goal is to evaluate acute individual response to an isolated 3 to 5 g dose (such as before sleep), verifying stability requires measuring paired fasting capillary glucose or tracking a continuous glucose sensor for 120 minutes post-ingestion.